ClinicalTrials.gg
CompletedNCT06841926Updated May 11, 2025

Study to Evaluate the Pharmacokinetics and Relative Bioavailability of Metabolites in Healthy Chinese Adult Males

A Phase 1 interventional study of ZX-7101A dry suspension and ZX-7101A tablet in Respiratory Viral Infection, sponsored by Nanjing Zenshine Pharmaceuticals. Completed at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-11.

Sponsored by Nanjing Zenshine Pharmaceuticals · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

Study to evaluate the pharmacokinetics and relative bioavailability of metabolites in healthy Chinese adult males

Read the detailed description

To evaluate the pharmacokinetic profile and relative bioavailability of the active metabolite ZX-7101 (parent drug) after a single oral administration of 40 mg ZX-7101A for suspension and 40 mg ZX-7101A tablet in healthy Chinese adult male subjects

02

Conditions studied

  • Respiratory Viral Infection
03

In context

Lead sponsor

Nanjing Zenshine Pharmaceuticals is the lead sponsor of 16 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subjects aged 18 to 45 years (including the cut-off value, subject to the signing of the )
  • (BMI) of 19 to 26 kg/m2 (including the cut-off value), with a body weight of at least 50 kg
  • Based on the medical history, physical examination, vital signs, 12-lead , laboratory tests (blood routine, urine routine, blood biochemistry, coagulation function), viral serology and chest X-ray results, the investigator judged that the subjects were in good general health (normal or abnormal examination results were not ).
  • Voluntary informed consent, no fertility and sperm donation plans within 90 days after the last dose of medication, and voluntary use of highly effective (including a partner) (Nonpharmacologic contraception was required during the clinical trial)
  • Before signing the informed consent, the patients should have a full understanding of the trial content, process and possible adverse reactions, and voluntarily sign the informed consent.
  • Be able to complete the study in accordance with the protocol requirements

Exclusion criteria

Exclusion Criteria:

  • Allergic (multiple drug and food allergies) or those who are likely to be allergic to the drug or any component of the investigational drug as judged by the investigator;
  • Subjects with taste and smell dysfunction
  • Oral ulcer or mucosal injury
  • Subjects with a previous or present medical history of clinically abnormal metabolic, hepatic, renal, hematologic, pulmonary, cardiovascular, gastrointestinal, urinary, endocrine, neurologic, or psychiatric disease who were deemed by the investigator to be ineligible for participation in the study
  • Subjects whose vital signs were abnormal and before administration
  • Subjects with abnormal white blood cell or before administration that was judged by the investigators to be clinically significant;
  • Before administration, the subjects had abnormal liver function: total >1.5× (ULN), >1.5× ULN, ALT >1.5× ULN;
  • Estimated \<90 mL/min/1.73 m2 (eGFR formula)
  • > 450ms (Fridericia's correction, QTcF=QT/(RR\^0.33)), QRS>120ms
  • Acute respiratory infection within 2 weeks before the study
  • Subjects who have difficulty swallowing drugs or have a history of gastrointestinal diseases that seriously affect drug absorption (including but not limited to reflux esophagitis, chronic diarrhea, inflammatory bowel disease, etc.); Or have a history of gastrointestinal surgery or resection that may alter the absorption and/or excretion of oral medications (subjects who have undergone appendectomy may be included)
  • Use of any prescription drug or Chinese herbal medicine within 4 weeks before trial initiation and use of over-the-counter or nutrual products (including multivalent cations, inhibitors, and metal supplements) within 2 weeks before trial initiation would require a longer interval of at least 5 half-ages of the drug
  • Subjects who had consumed more than 14 units of alcohol per week (1 unit =360 mL of beer or 45 mL of 40% spirits or 150 mL of wine) in the 6 months before screening or had received a positive breath test for alcohol
  • Smoking more than five cigarettes per day or habitual use of nicotine-containing products in the 3 months before screening.
  • Subjects who were unwilling to abstain from foods or drinks containing caffeine or alcohol that affect drug metabolism within 72 hours before drug administration and during the period of observation in phase I ward.
  • Use of any known liver enzyme inducer or liver enzyme inhibitor (grapefruit, orange juice, etc.) within 14 days before administration.
  • Subjects with a history of drug abuse (morphine, dimethyldioxyamphetamine, methamphetamines, tetrahydrocannabinol, ketamine, cocaine) or screening positive for drug abuse;
  • Subjects who were serologically positive for syphilis antibody (TP-trust), surface antigen, virus antibody or antibody;
  • Donating >400 mL within 3 months or >200 mL within 4 weeks prior to the screening period or planning to donate during the study period;
  • Those who have difficulty in venous blood collection;
  • Subjects who participated in other clinical trials or used any other clinical trial drugs or devices within 3 months before screening;
  • Vaccinated within 1 month prior to dose or planned to be vaccinated during the study period;
  • Subjects who had a surgical procedure within 6 months before screening or who were scheduled to undergo surgery during the trial;
  • Any other situation that the investigator considers may affect the subject's provision of or compliance with the trial protocol or completion of the trial according to the study process, or the subject's participation in the trial may affect the trial results or their own safety.Subjects who were serologically positive for syphilis antibody (TP-trust), hepatitis B surface antigen, hepatitis C virus antibody or human immunodeficiency virus antibody;
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Other
    The test preparation was followed by the reference preparation

    Group 1: The test preparation was followed by the reference preparation: 20 subjects were given the test formulation (T) : ZX-7101A dry suspension 40 mg (4 bags) orally in the first cycle, and crossed over to the reference formulation ZX-7101A tablets 40 mg (1 tablet) in the second cycle, with a wash period of at least 21 days between two weeks.

    Drug: ZX-7101A dry suspension · Other: ZX-7101A tablet

  • Other
    The reference preparation was followed by the test preparation

    Group 2: The reference preparation was followed by the test preparation: 20 subjects were given reference formulation ZX-7101A tablets 40 mg (1 tablet) orally in the first cycle, and crossed over to the the test formulation (T) : ZX-7101A dry suspension 40 mg (4 bags) in the second cycle, with a wash period of at least 21 days between two weeks.

    Drug: ZX-7101A dry suspension · Other: ZX-7101A tablet

Interventions

  • Test formulation (T) : ZX-7101A dry suspension Specification: 10 mg/ bag Dosage:40 mg (4 bags)、 once

  • OtherZX-7101A tablet

    Reference formulation (R): ZX-7101A tablet Specification: 40 mg/ tablet Dosage:40 mg (1 tablet)、 once

06

What researchers measure

Primary outcomes

  1. The pharmacokinetic parameters Cmax of the active metabolite ZX-7101 (parent drug)

    Pharmacokinetic parameters Cmax of the active metabolite ZX-7101 (parent drug) in plasma after administration of ZX-7101A dry suspension /ZX-7101A tablets

    Time frame: From Day1 up to Day 36

  2. The pharmacokinetic parameters AUC0-t of the active metabolite ZX-7101 (parent drug)

    Pharmacokinetic parameters AUC0-t of the active metabolite ZX-7101 (parent drug) in plasma after administration of ZX-7101A dry suspension /ZX-7101A tablets

    Time frame: From Day1 up to Day 36

  3. The pharmacokinetic parameters AUC0-inf of the active metabolite ZX-7101 (parent drug)

    Pharmacokinetic parameters AUC0-inf of the active metabolite ZX-7101 (parent drug) in plasma after administration of ZX-7101A dry suspension /ZX-7101A tablets

    Time frame: From Day1 up to Day 36

  4. Relative bioavailability of the active metabolite ZX-7101 (parent drug)

    Relative bioavailability of the active metabolite ZX-7101 (parent drug) in plasma after administration of ZX-7101A dry suspension /ZX-7101A tablets.

    Time frame: From Day1 up to Day 36

Secondary outcomes

  1. Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE v5.0

    To evaluate the safety and tolerability of a single oral administration of ZX-7101A dry suspension (40 mg/tablet) in healthy Chinese adult male subjects

    Time frame: From Day 1 up to Day 36

  2. Cmax

    To evaluate the pharmacokinetic: Cmax of ZX-7101A (prodrug) after a single oral administration of ZX-7101A dry suspension 40 mg and ZX-7101A tablets 40 mg in healthy Chinese adult male subjects

    Time frame: From Day 1 up to Day 36

  3. AUC0-t

    To evaluate the pharmacokinetic: AUC0-t of ZX-7101A (prodrug) after a single oral administration of ZX-7101A dry suspension 40 mg and ZX-7101A tablets 40 mg in healthy Chinese adult male subjects

    Time frame: From Day 1 up to Day 36

  4. AUC0-inf

    To evaluate the pharmacokinetic:AUC0-inf of ZX-7101A (prodrug) after a single oral administration of ZX-7101A dry suspension 40 mg and ZX-7101A tablets 40 mg in healthy Chinese adult male subjects

    Time frame: From Day 1 up to Day 36

  5. Evaluation of palatability

    The proportion of all subjects who received ZX-7101A dry suspension with a score ≥50 (including not good not bad, good, very good)

    Time frame: On Day 1

  6. Tmax

    PK parameters of prodrug ZX-7101A and its active metabolite ZX-7101 (parent drug) : Tmax

    Time frame: From Day 1 up to Day 36

  7. Vz/F

    PK parameters of prodrug ZX-7101A and its active metabolite ZX-7101 (parent drug) : Vz/F

    Time frame: From Day 1 up to Day 36

  8. CL/F

    PK parameters of prodrug ZX-7101A and its active metabolite ZX-7101 (parent drug) : CL/F

    Time frame: From Day 1 up to Day 36

  9. t1/2

    PK parameters of prodrug ZX-7101A and its active metabolite ZX-7101 (parent drug) : t1/2

    Time frame: From Day 1 up to Day 36

  10. λz

    PK parameters of prodrug ZX-7101A and its active metabolite ZX-7101 (parent drug) : λz

    Time frame: From Day 1 up to Day 36

07

Study locations

1 site
  • West China Second University Hospital, Sichuan University and Children's Hospital Zhejiang University School of Medicine
    Chengdu, Sichuan 610041, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2025 to primary completion in Apr 2025, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2025
First posted
Feb 24, 2025
StartActual
Feb 20, 2025
Primary completionActual
Apr 18, 2025
CompletionActual
Apr 18, 2025
Last update
May 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06841926
Lead sponsor
Nanjing Zenshine Pharmaceuticals
Responsible party
Sponsor
First posted
Feb 24, 2025
Start date
Feb 20, 2025
Primary completion
Apr 18, 2025
Completion
Apr 18, 2025
Last update
May 11, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ZX-7101A

Start the discussion